Hofseth BioCare ASA (HOFBF)
| Previous Close | 0.2200 |
| Open | 0.2200 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.2200 - 0.2200 |
| 52 Week Range | 0.2200 - 1.0000 |
| Volume | |
| Avg. Volume | 0 |
| Market Cap | 86.917M |
| Beta (5Y Monthly) | 0.44 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0200 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GlobeNewswireHofseth Biocare ASA: NOTICE OF ANNUAL GENERAL MEETING 2024
The Annual General Meeting of Hofseth BioCare ASA for 2024 will be held at the company's premises at Keiser Wilhelms gate 24, 6003 Ålesund, on 10 May 2024 at 13:00 CET. The notice of the Annual General Meeting is attached. For further information, please contact: Jon Olav Ødegård, CEO of Hofseth BioCare ASA Phone: +47 93632966 E-mail: investor@hofsethbiocare.no About Hofseth BioCare ASA: HBC is a Norwegian consumer and pet health ingredient supplier and an incubator for new pharmaceutical drug l
- GlobeNewswire
Hofseth Biocare ASA: HBC ANNUAL REPORT 2023
The Board of Directors of Hofseth BioCare ASA ("HBC") has approved the financial statements for 2023 and the Company has today published the Annual Report and Sustainability Report for 2023. Please find the Annual Report and ESG Report attached. For further information, please contact:Christel Elise Kanli, CFO of Hofseth BioCare ASAPhone: +47 41623188E-mail: ck@hofsethbiocare.no About Hofseth BioCare ASA: HBC is a Norwegian consumer and pet health ingredient supplier and an incubator for new pha
- GlobeNewswire
Hofseth Biocare ASA: UPDATED COMPANY PRESENTATION
Please find the HBC Company Presentation attached. For further information, please contact: James Berger, Chief Commercial Officer of Hofseth BioCare ASA Phone: +41 79 950 10 34 E-mail: jb@hofsethbiocare.no About Hofseth BioCare ASA: HBC is a Norwegian consumer and pet health ingredient supplier and an incubator for new pharmaceutical drug leads. Research is ongoing to identify the individual elements within its ingredients that modulate inflammation and the immune response with pre-clinical stu
